IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1313.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 10-Sep-2015
Cell Reports
Blood cancers develop when immune cell DNA editing hits off-target spots
Editing errors in the DNA of developing T and B cells can cause blood cancers. Now, researchers have shown that when the enzyme key to cutting and pasting segments of DNA hits so-called 'off-target' spots on a chromosome, the development of immune cells can lead to cancer in animal models. Knowing the exact nature of these editing errors will be helpful in designing therapeutic enzymes based on these molecular scissors.
NIH/National Cancer Institute

Contact: Karen Kreeger
University of Pennsylvania School of Medicine

Public Release: 10-Sep-2015
Which patients will respond to melanoma immunotherapy?
Patients with metastatic melanoma who have benefited from a new type of cancer immunotherapy don't appear to share the same tumor-produced antigens, according to a new report by Eliezer Van Allen and colleagues.

Contact: Natasha Pinol
American Association for the Advancement of Science

Public Release: 10-Sep-2015
Gastrointestinal Endoscopy
Changing patient's position helps effectiveness of colonoscopy -- especially on one side
Having patients lie on their left side while the right side of their colon is being examined can result in more polyps being found, thus increasing the effectiveness of colonoscopy for colorectal cancer screening, according to a study in the September issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

Contact: Gina Steiner
American Society for Gastrointestinal Endoscopy

Public Release: 10-Sep-2015
Cancer Epidemiology
Breast cancer incidence, death rates rising in some economically transitioning countries
A new study finds breast cancer incidence and death rates are increasing in several low and middle income countries, even as death rates have declined in most high income countries, despite increasing or stable incidence rates.
American Cancer Society

Contact: David Sampson
American Cancer Society

Public Release: 10-Sep-2015
Cell Reports
Errant gene turns cells into mobile cancer factories
Salk scientists have found a key molecular mechanism that underlies deadly behavior in hard-to-treat breast cancer.

Contact: Salk Communications
Salk Institute

Public Release: 10-Sep-2015
Telomerase can be successfully targeted by a highly specific inhibitor
New research from The Wistar Institute shows exactly how a known, highly selective small molecule telomerase inhibitor is able to bind with the enzyme, thus opening the possibility of developing more telomerase inhibitors that target this pocket of telomerase and could be clinically effective in a wide variety of cancer types.
NIH/National Institute of General Medical Sciences

Contact: Ben Leach
The Wistar Institute

Public Release: 10-Sep-2015
Chemistry and Biology
GI side effects of chemotherapy reduced in mice by targeting gut microbes
The blame for some of chemotherapy's awful side effects may lie with our gut microbes, early evidence suggests. As chemotherapy drugs are eliminated from the body, bacteria in the gastrointestinal tract can latch onto them and transform them into toxic species that cause severe diarrhea. In Chemistry & Biology researchers present ways to shut down the ability of GI microbes to convert chemotherapy drugs in mice as a first step to helping cancer patients.

Contact: Joseph Caputo
Cell Press

Public Release: 10-Sep-2015
Stanford scientists produce cancer drug from rare plant in lab
Stanford scientists produced a common cancer drug -- previously only available from an endangered plant -- in a common laboratory plant. This work could lead to a more stable supply of the drug and allow scientists to manipulate that drug to make it even safer and more effective.
US National Institutes of Health

Contact: Amy Adams
Stanford University

Public Release: 10-Sep-2015
Cancer preventative surgery could become a thing of the past, new research suggests
Surgery to remove the breasts of women at increased risk of developing breast cancer may not be necessary in the future, according to research published in EBioMedicine. Two new studies looking at the effect the menstrual cycle has on the development of breast and ovarian cancer reveal alternative prevention strategies that may render surgery unnecessary.

Contact: Nienke Swankhuisen

Public Release: 10-Sep-2015
Rare plant reveals its recipe for potent chemotherapeutic agent
Inconveniently, the only current method to synthesize the chemotherapy agent etoposide is by using extracts from a plant, but researchers have successfully manipulated Nicotiana benthamiana (tobacco) to create a more immediate and potent precursor.

Contact: Natasha Pinol
American Association for the Advancement of Science

Public Release: 10-Sep-2015
Cell Metabolism
Pancreatic cancer stem cells could be 'suffocated' by an anti-diabetic drug
A new study shows that pancreatic cancer stem cells are virtually addicted to oxygen-based metabolism, and could be 'suffocated' with a drug already used to treat diabetes.

Contact: Will Hoyles
Queen Mary, University of London

Public Release: 10-Sep-2015
Blood Cancer Journal
Discovery offers hope for treating leukemia relapse post-transplant
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia relapse after a stem cell transplant, according to Penn State College of Medicine researchers.
American Cancer Society, Kiesendahl Endowment

Contact: Matt Solovey
Penn State

Public Release: 10-Sep-2015
Nature Communications
Clearing a path for cancer research
Researchers at EMBL's European Bioinformatics Institute have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry experiments. The study is published in Nature Communications.
European Molecular Biology Laboratory, Barts Charity, Cancer Research UK

Contact: Sonia Furtado Neves and Mary Todd Bergman
European Molecular Biology Laboratory

Public Release: 10-Sep-2015
Cell-surface discovery could fundamentally alter cancer treatment
Researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.
NIH/Fogarty International Center, Bill and Melinda Gates Foundation, Wallace H. Coulter Translational Research Partnership Endowment, Paul Mellon Urologic Oncology Institute

Contact: Josh Barney
University of Virginia Health System

Public Release: 10-Sep-2015
Nature Communications
New protein manufacturing process unveiled
Researchers from Northwestern University and Yale University have developed a user-friendly technology to help scientists understand how proteins work and fix them when they are broken. Such knowledge could pave the way for new drugs for a myriad of diseases, including cancer. The researchers' cell-free protein synthesis platform technology can manufacture large quantities of phosphorylated human proteins for scientific study. This will enable scientists to learn more about their function, structure and role in disease.
National Institutes of Health, Defense Advanced Research Projects Agency, David and Lucille Packard Foundation

Contact: Megan Fellman
Northwestern University

Public Release: 10-Sep-2015
Annals of Internal Medicine
New risk score for colorectal cancer could guide selection of screening tests
Researchers at the Regenstrief Institute and the Indiana University School of Medicine have developed a new risk assessment scoring system that could help physicians judge which patients can forgo invasive colonoscopy testing for cancer screening and which should receive the test.
NIH/National Cancer Institute, Walther Cancer Institute, Indiana University Melvin and Bren Simon Cancer Center, Indiana Clinical and Translational Sciences Institute

Contact: Lisa Welch
Regenstrief Institute

Public Release: 10-Sep-2015
Cellular and Molecular Gastroenterology and Hepatology
New DNA testing for liver cancer could improve survival
Detection of small fragments of tumor DNA, known as circulating tumor DNA, in a patient's pre-surgery serum samples predicts early recurrence of hepatocellular carcinoma and may guide treatment, according to a study published in Cellular and Molecular Gastroenterology and Hepatology.

Contact: Rachel Steigerwald
American Gastroenterological Association

Public Release: 10-Sep-2015
AGA recommends all patients with colorectal cancer get tested for Lynch syndrome
All colorectal cancer patients should undergo tumor testing to see if they carry Lynch syndrome, the most common inherited cause of colorectal cancer, according to a new guideline was published in Gastroenterology, the official journal of the American Gastroenterological Association.

Contact: Aimee Frank
American Gastroenterological Association

Public Release: 9-Sep-2015
16th World Conference on Lung Cancer
Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe
Pembrolizumab, an immunotherapy drug that unmasks cancer cells and allows the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America at Western Regional Medical Center. Dr. Glen Weiss is the first author of the study abstract: Phase Ib/II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) one prior line of therapy.

Contact: Steve Yozwiak
Cancer Treatment Centers of America

Public Release: 9-Sep-2015
16th World Conference on Lung Cancer
Study defines clinical trials likely to exclude patients with brain metastases
A CU Cancer Center study being presented at the 16th World Conference on Lung Cancer defines characteristics of cancer clinical trials that are likely to exclude patients with brain metastases.

Contact: Garth Sundem
University of Colorado Anschutz Medical Campus

Public Release: 9-Sep-2015
Scientific Reports
Nearly half of testicular cancer risk comes from inherited genetic faults
Almost half of the risk of developing testicular cancer comes from the DNA passed down from our parents, a new study reports. The research suggests genetic inheritance is much more important in testicular cancer than in most other cancer types, where genetics typically accounts for less than 20 percent of risk.
Movember Foundation, Institute of Cancer Research, Cancer Research UK

Contact: Henry French
Institute of Cancer Research

Public Release: 9-Sep-2015
Journal of Physical Chemistry B
How the 'heat' compound from chili peppers could help kill cancer cells
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form. Their study appears in ACS' The Journal of Physical Chemistry B.

Contact: Michael Bernstein
American Chemical Society

Public Release: 9-Sep-2015
Natural compound could reduce breast cancer risk in some women
The odds of women being diagnosed with breast cancer increase in postmenopausal women who have taken a combined estrogen and progestin hormone replacement therapy; these women also have an increased risk of developing progestin-accelerated breast tumors. Now, University of Missouri researchers have found that luteolin, a natural compound found in herbs such as thyme and parsley as well as vegetables such as celery and broccoli, could reduce the cancer risk for women who have taken hormone replacement therapy.

Contact: Jeff Sossamon
University of Missouri-Columbia

Public Release: 9-Sep-2015
New England Journal of Medicine
Penn team: Sustained remission of multiple myeloma after personalized cellular therapy
A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania. The investigational treatment was combined with chemotherapy and an autologous stem cell transplant -- a new strategy designed to target and kill the cells that give rise to myeloma cells.
Novartis, National Institutes of Health, Conquer Cancer Foundation

Contact: Holly Auer
University of Pennsylvania School of Medicine

Public Release: 9-Sep-2015
A hint of increased brain tumor risk -- 5 years before diagnosis
A new study suggests that changes in immune function can occur as long as five years before the diagnosis of a brain tumor that typically produces symptoms only three months before it is detected.
NIH/National Cancer Institute, National Institutes of Health, Ohio State University Comprehensive Cancer Center

Contact: Judith Schwartzbaum
Ohio State University

Showing releases 176-200 out of 1313.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases